美多芭联合盐酸普拉克索治疗对帕金森病患者焦虑抑郁状态及血清炎症因子水平的影响

Effect of madopar combined with pramipexole dihydrochloride on anxiety and depression and serum inflammatory factors of patients with Parkinson's disease

目的研究美多芭联合盐酸普拉克索治疗对帕金森病患者焦虑抑郁状态及血清炎症因子水平的影响。方法收集2013年1月~2016年1月收治入院的帕金森患者200例作为研究对象,随机分为对照组和观察组。对照组100例给予美多芭片治疗,观察组在对照组的基础上给予盐酸普拉克索片,疗程均为12周,评估患者治疗前后焦虑抑郁程度,采取酶联免疫吸附试验方法检测两组患者治疗前后肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、白细胞介素-10(IL-10)等水平,对比两组不良反应,并进行统计学分析。结果观察组总有效率为95.0%(95/100),对照组总有效率为74.0%(74/100),两组比较观察组高于对照组(P<0.05);两组间比较治疗12周后,两组SDS评分及SAS评分均有降低,与治疗前比较均有统计学意义(P<0.05);观察组患者治疗后的SDS评分及SAS评分下降程度优于对照组,两组比较差异具有统计学意义(P<0.05);观察组患者治疗后内毒素、TNF-α、IL-6、IL-10等细胞因子对照组治疗比较差异均有统计学意义(P<0.05);观察组治疗后不良反应发生率明显低于对照组,差异有统计学意义(χ~2=8.946,P<0.05)。结论联合盐酸普拉克索和美多芭治疗帕金森病有效且安全,可明显改善患者焦虑抑郁状态,有效清除患者血清炎症因子,值得临床推广。

Objective To study the effect of madopar combined with pramipexole dihydrochloride on anxiety and depression and serum inflammatory factors of patients with Parkinson＇s disease. Methods 200 patients with Parkinson＇s disease who were admitted to our hospital from January 2013 to January 2016 were selected as research objects and they were randomly divided into the control group and the observation group.100 patients in the control group were given madopar for treatment and the observation group was given pramipexole dihydrochloride at the basis of control group.A course of treatment was 12 weeks.Anxiety and depression before and after treatment of patients were evaluated.In addition,tumor necrosis factor-α （TNF-α）,interleukin-6（IL-6） and interleukin-10 （IL- l0） before and after treatment were tested by enzyme-linked immunosorbent assay （ELISA）.Adverse effects of two groups were compared and statistically analyzed. Results The total effective rate of the observation group was 95.0% （95/100）,higher than that of the control group 74.0% （74/100） （P 〈 0.05）.SDS scores and SAS scores of 12 weeks after treatment of two groups were both decreased.There was statistical significance compared with those before treatment （P 〈 0.05）.After treatment, decreasing degrees of SDS score and SAS score of patients in the observation group were superior to those of the control group.Comparative differences of two groups had statistical significance （P 〈 0.05） respectively）.After treatment,difference in endotoxin,TNF-α ,IL-6 and IL-10 of the observation group and the control group had statistical significance （P 〈 0.05）.Incidence of adverse reactions after treatment in the observation group was significantly lower than that of the control group.The difference was statistical significant （χ2=8.946,P 〈 0.05）. Conclusion Pramipexole dihydrochloride combined with madopar in treatment of Parkinson＇ s disease is effective and safe.h can not only significantly improve anxiety and depression but also effectively clear serum inflammatory factors,which is worthy of clinical promotion.